Latest news with #IntegratedDNATechnologies
Business Wire
16-07-2025
- Health
- Business Wire
Integrated DNA Technologies Announces Translational CRISPR Portfolio Expansion with Product Innovation Updates
CORALVILLE, Iowa--(BUSINESS WIRE)--Global genomics leader Integrated DNA Technologies (IDT) is revolutionizing the field of translational gene editing with new additions to its end-to-end CRISPR portfolio. These expanded CRISPR translational research solutions are designed to help researchers accelerate more CRISPR-based therapies for patients like KJ Muldoon, an infant who suffered CPS1 deficiency and made history when he received the world's first personalized CRISPR therapy manufactured jointly by IDT and Aldevron. IDT provided the guide RNA (gRNA), off-target analysis services and regulatory support for baby KJ's treatment, which was delivered in a significantly compressed timeline. 'IDT's rich history, deep expertise, and ability to manufacture bespoke products at the highest quality uniquely positions us to consistently innovate on our CRISPR portfolio and support customers at every stage of their gene editing journey' Share Tailored gRNAs to Accelerate CRISPR Discoveries As researchers advance from discovery to clinical applications, the demand for higher purity in CRISPR reagents increases. To meet this need, IDT's chemically synthesized gRNAs are now available for online ordering in a range of modification and purity options. With high purity ideal for translational applications such as gene editing in primary cells and in vivo models, IDT's high-performance liquid chromatography (HPLC)-purified gRNAs are orderable in 2 nmol and 10 nmol yields with larger quantities available by request and ship in as little as 12 business days. Formats include CRISPR-Cas9 gRNA and Custom Alt-R™ CRISPR gRNA. 2' Fluoro, 2' O-Methyl, and other modifications can be added to increase stability and specificity with IDT's custom gRNA tool. Supporting Scientists with Regulatory Filings and Ensuring Safety of Therapeutic Candidates CRISPR-based genome editing allows for targeted editing at specific sites in the genome, but there is potential risk that off-target edits at other locations can occur. To enable scientists to understand where these off-target edits might happen and assess how they might impact safety early in the therapeutic development process, IDT launched UNCOVERseq, off-target nomination services which uses an enhanced GUIDE-seq™ methodology to identify off-target sites for its customers. When paired with IDT's award-winning off-target confirmation services, rhAmpSeq™ CRISPR Analysis System, CRISPR pioneers can confidently accelerate their path to the clinic by obtaining a deeper understanding of editing risks. The custom safety services provided in baby KJ's treatment helped launch UNCOVERseq and represent a major step forward in ensuring the safety of CRISPR-based therapies. Enhancing Safety, Quality and Efficiency: IDT's Growing Pipeline and Future Collaborations Future IDT launches, planned for late 2025, include complementary offerings such as the Alt-R HDR Enhancer Protein, which is designed specifically for therapeutic applications, and manufactured by Aldevron, to meet rigorous quality standards. The HDR Enhancer Protein improves HDR efficiency in difficult-to-edit cells, and maintains safety and cell health. IDT, in collaboration with Aldevron, will also be launching a novel Cas9 mRNA to support early discovery to clinical stage customers. IDT has been a long-time provider of CRISPR gRNA libraries for screening applications and will unveil a new design tool later this year for efficient ordering of custom, configured libraries. 'IDT's rich history, deep expertise, and ability to manufacture bespoke products at the highest quality uniquely positions us to consistently innovate on our CRISPR portfolio and support customers at every stage of their gene editing journey,' said Sandy Ottensmann, VP/GM, Gene Writing & Editing at IDT. 'On the heels of the world's first personalized CRISPR-based therapy, we're honored to bring more CRISPR tools that will enable researchers to make important discoveries, like the one designed for baby KJ, and progress science forward.' Learn more about IDT's CRISPR portfolio here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations. Disclaimer: CGMP refers to products manufactured under ICHQ7; IDT engineering runs and CGMP gRNA are for development and investigational use only. The performance characteristics of this product have not been established. This product is not intended to be used as final drug product. The purchaser is solely responsible for all decisions regarding the intended use of the product and any associated legal or regulatory obligations. GUIDE-seq™ is owned by Maxcyte®, Inc.
Business Wire
10-07-2025
- Business
- Business Wire
IDT Launches All-Inclusive Gene Fragments From 7 Cents Per Base With 25% Lower Turnaround Times and Next-Day Shipping Powered by Its Cutting-Edge Synthetic Biology Facility
CORALVILLE, Iowa--(BUSINESS WIRE)--Global genomics solutions leader Integrated DNA Technologies (IDT), with an established reputation in scientific leadership and high-quality solutions for customers, has announced a brand-new center focused on custom genes. Driven by the capabilities made possible by this new center, IDT has expanded its high-quality offerings to customers via a new synthetic biology custom solutions team and has made significant improvements in their market-leading synthetic biology manufacturing capabilities. 'Our mission has always been to empower scientists to develop solutions that matter to customers and move faster without compromising quality,' said Ajay Gannerkote, President of IDT. Share As the first to develop gBlocks™ Gene Fragments, IDT set the standard for fast, affordable, and high-quality synthetic DNA—and continues to raise the bar by developing customizable solutions tailored to any research challenge. Today, IDT's eBlocks™ Gene Fragments and SynBio Custom Solutions are helping scientists move from idea to experiment faster than ever, with fragments often shipping the next day, transparent pricing starting at $0.07/bp USD, and no hidden fees or adapter removal steps. These improvements apply to its leading gene fragment products such as eBlocks, gBlocks, and gBlocks HiFi Gene Fragments, including standard and rapid gene clonal products. This continuous improvement is due to the further implementation of the Danaher Business System (DBS) and new investments. In a field where speed and precision are critical, IDT continues to lead with the innovation and reliability researchers have trusted for nearly four decades. Led by science and quality, built for speed. Cloning-ready convenience —no adapter removal required. Compatible with major cloning techniques. Clone straight from tube to vector. Higher yields, fewer reorders —200 ng minimum yield for gene fragments means fewer reorders and more flexibility. Next-day shipping —eBlocks ship in as fast as 24 hours, with consistent, transparent pricing – no surprises. 'Our mission has always been to empower scientists to develop solutions that matter to customers and move faster without compromising quality,' said Ajay Gannerkote, President of IDT. 'We were the first to bring gBlocks Gene Fragments to the market, and we've never stopped innovating. Today, we continue to invest in our platforms and infrastructure to push turnaround times even further—because accelerating discovery is what we do best.' Beyond the catalog: Tailor-made solutions for pioneering science Not every project fits in a catalog. Through its SynBio Custom Solutions Team IDT partners directly with researchers to design and deliver tailor-made solutions, including codon optimization, vector selection, and expression tuning—ensuring each construct is designed around the researcher's goals, not vendor limitations. Backed by over 35 years of scientific leadership and a team of specialized PhD scientists, IDT helps accelerate next-generation breakthroughs that require more than off-the-shelf tools, bringing even the most ambitious ideas to life. Why the world's top labs choose IDT Pioneers of gBlocks Gene Fragments Trusted by leading academic institutions and biotech innovators worldwide Responsive, expert support when your experiment is on the line Always solving for customers No hidden fees, no surprises—just results Whether you're starting an experiment this week or engineering biology for the future, IDT remains the partner you've always counted on—for science, quality, speed, precision, and trust. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. . Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use.
Yahoo
16-06-2025
- Business
- Yahoo
Integrated DNA Technologies Announces Innovation Roadmap Advances to Infectious Disease Portfolio
Expanded portfolio offerings include first-to-market product launches to support global health challenges New infectious disease research solutions to be spotlighted at ASM Microbe 2025 CORALVILLE, Iowa, June 16, 2025--(BUSINESS WIRE)--Integrated DNA Technologies (IDT), a global genomics leader, is expanding its infectious disease portfolio with new solutions to enhance worldwide research efforts in monitoring infectious disease dynamics, supporting surveillance and accelerating biomarker discovery. As part of its innovation roadmap, focused on enabling academic and medical researchers, health organizations, and the scientific community prepare for ongoing and future global health challenges, IDT has unveiled two new powerful tools: The PrimeTime™ Influenza Kit and PrimeTime Research Pathogen Panels. These differentiated offerings expand upon IDT's current infectious disease portfolio of qPCR and next generation sequencing (NGS) solutions comprised of stand-alone library preparation, target enrichment and normalization chemistries, as well as connected DNA solutions, to support researchers exploring viral evolution, epidemiological studies, drug resistance mechanisms, drug development research and more. First to Market: Complete Solution for Influenza Research Launching at ASM Microbe 2025 is IDT's PrimeTime Influenza Kit, the first complete qPCR solution of its kind designed specifically to amplify common influenza strains. The kit targets Influenza A, Influenza A (H5N1), Influenza B, and RNase. It includes an internal control for sample quality assessment, a pre-mixed primer and probe set, PrimeTime 4x Broad-Range Master Mix and direct amplification enhancer. This streamlined solution enables researchers to generate high-confidence data for both seasonal and emerging influenza strains. New Cost-effective Solution to Accelerate Sexual Health and Pathogen Research IDT is also showcasing its new PrimeTime Research Pathogen Panels, a customizable, high-throughput solution that allows researchers to identify key sequences and mutations across 10 diverse research applications—spanning respiratory, gastrointestinal and sexual health studies—and an 11th category for viral infection research. The mix-and-match format across targets and dyes enables scientists to select from a broad list of targets to maximize cost and time savings. The panels' flexible assay configuration facilitates rapid, multiplexed detection and characterization of pathogens, with up to 211 available targets including sexually transmitted infections, human papillomavirus, urinary tract infections and more. With seamless integration into existing qPCR workflows, this single-tube offering equips researchers with innovative tools for exploring pathogen dynamics across individual and population-level studies. "Building on IDT's storied impact on the global fight against infectious diseases, these new tools reflect the ongoing innovation investments we're making to empower researchers to stay ahead of current and emerging health challenges," said Adler Edward, VP, Gene Reading Components at IDT. "By delivering robust, customizable and high-quality solutions, backed by IDT's trusted technical and scientific expertise, researchers can feel confident in accelerating their discoveries and deepening their understanding of pathogen dynamics in human health." To learn more about IDT's infectious disease innovation roadmap and how these new offerings are shaping the future of virus transmission research, visit IDT at ASM Microbe 2025 at booth #1723. To place an order, click here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations. View source version on Contacts Media Contacts:Integrated DNA Technologies idtpr@ 800-328-2661 (USA & Canada)+1 319-626-8400 (outside USA) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
16-06-2025
- Health
- Business Wire
Integrated DNA Technologies Announces Innovation Roadmap Advances to Infectious Disease Portfolio
CORALVILLE, Iowa--(BUSINESS WIRE)-- Integrated DNA Technologies (IDT), a global genomics leader, is expanding its infectious disease portfolio with new solutions to enhance worldwide research efforts in monitoring infectious disease dynamics, supporting surveillance and accelerating biomarker discovery. As part of its innovation roadmap, focused on enabling academic and medical researchers, health organizations, and the scientific community prepare for ongoing and future global health challenges, IDT has unveiled two new powerful tools: The PrimeTime™ Influenza Kit and PrimeTime Research Pathogen Panels. These differentiated offerings expand upon IDT's current infectious disease portfolio of qPCR and next generation sequencing (NGS) solutions comprised of stand-alone library preparation, target enrichment and normalization chemistries, as well as connected DNA solutions, to support researchers exploring viral evolution, epidemiological studies, drug resistance mechanisms, drug development research and more. 'Building on IDT's storied impact on the global fight against infectious diseases, these new tools reflect the ongoing innovation investments we're making to empower researchers to stay ahead of current and emerging health challenges,' said Adler Edward. Share First to Market: Complete Solution for Influenza Research Launching at ASM Microbe 2025 is IDT's PrimeTime Influenza Kit, the first complete qPCR solution of its kind designed specifically to amplify common influenza strains. The kit targets Influenza A, Influenza A (H5N1), Influenza B, and RNase. It includes an internal control for sample quality assessment, a pre-mixed primer and probe set, PrimeTime 4x Broad-Range Master Mix and direct amplification enhancer. This streamlined solution enables researchers to generate high-confidence data for both seasonal and emerging influenza strains. New Cost-effective Solution to Accelerate Sexual Health and Pathogen Research IDT is also showcasing its new PrimeTime Research Pathogen Panels, a customizable, high-throughput solution that allows researchers to identify key sequences and mutations across 10 diverse research applications—spanning respiratory, gastrointestinal and sexual health studies—and an 11th category for viral infection research. The mix-and-match format across targets and dyes enables scientists to select from a broad list of targets to maximize cost and time savings. The panels' flexible assay configuration facilitates rapid, multiplexed detection and characterization of pathogens, with up to 211 available targets including sexually transmitted infections, human papillomavirus, urinary tract infections and more. With seamless integration into existing qPCR workflows, this single-tube offering equips researchers with innovative tools for exploring pathogen dynamics across individual and population-level studies. 'Building on IDT's storied impact on the global fight against infectious diseases, these new tools reflect the ongoing innovation investments we're making to empower researchers to stay ahead of current and emerging health challenges,' said Adler Edward, VP, Gene Reading Components at IDT. 'By delivering robust, customizable and high-quality solutions, backed by IDT's trusted technical and scientific expertise, researchers can feel confident in accelerating their discoveries and deepening their understanding of pathogen dynamics in human health.' To learn more about IDT's infectious disease innovation roadmap and how these new offerings are shaping the future of virus transmission research, visit IDT at ASM Microbe 2025 at booth #1723. To place an order, click here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
Business Wire
05-05-2025
- Business
- Business Wire
Integrated DNA Technologies Brings Innovation Nexus to San Francisco Bay Area
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Global genomics solutions leader Integrated DNA Technologies (IDT) is investing technological capabilities and resources to launch a new innovation hub and support the Bay Area biotech cluster. Located at IDT's Redwood City site, in lockstep with its research and development (R&D) facility, the innovation nexus will serve as a collaboration center that enables IDT to innovate with regional customers, forge strategic partnerships, and drive R&D initiatives with leading-edge biotechnology companies. 'The installation of IDT's Innovation Nexus reflects our commitment to engaging closely with customers and strategic partners, and equipping them with novel solutions, tools of unrivalled quality, and trusted expertise,' said Linda De Jesus. Share The establishment of the innovation nexus is a pivotal element of IDT's strategic roadmap, aimed at acquiring emerging and transformative synthesis technologies ranging from novel chemistries, enzymatic synthesis, and alternative platforms, and driving market growth in precision oncology through advanced next generation sequencing (NGS) applications. Today, the company's NGS portfolio is comprised of xGen™ offerings which include standalone library preparation, target enrichment and normalization chemistries, as well as IDT Archer connected NGS solutions with end-to-end assay platforms, including secondary analysis capabilities and seamless tertiary software integrations. These differentiated solutions have been indispensable to cancer researchers, who rely on strong cancer insights, including both high-quality sequencing and data interpretation. 'The installation of IDT's Innovation Nexus reflects our commitment to engaging closely with customers and strategic partners, and equipping them with novel solutions, tools of unrivalled quality, and trusted expertise,' said Linda De Jesus, VP/GM Global Head of Commercial at Integrated DNA Technologies. 'Building off of our strong foundation in oligo synthesis technologies, IDT today is more than oligos, and we're proud of the evolution we're making to continually innovate with customers, to bring them high-quality technical capabilities and deep scientific knowledge.' The IDT Innovation Nexus complements IDT's rich legacy of innovation, which stems from its origins in Coralville, Iowa. Today, the company's Coralville headquarters remain a center of innovation with its oligo synthesis capabilities, which the company continually optimizes for high-throughput approaches. The Redwood City-based Innovation Nexus also welcomes a new IDT leader with more than a decade of experience who will spearhead the transformation and adoption of new technologies to meet customer needs. The newly created position will oversee a team of scientific experts in transforming IDT's technical capabilities, with a dedicated focus on R&D efforts that will build upon IDT's legacy portfolio and proven expertise in oligo synthesis technologies. To learn how IDT's innovative genomic solutions and bespoke capabilities are accelerating the world's greatest scientific breakthroughs, click here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
